Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + lenalidomide + dexamethasone versus lenalidomide + dexamethasone in high-risk smoldering multiple myeloma
2017-000555-10Phase 2Active
- Sponsor
- HOVON
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in smoldering multiple myeloma (SMM) comparing Carfilzomib + lenalidomide + dexamethasone with Lenalidomide + dexamethasone (2 arms). Primary endpoint: MRD negativity rate by next-generation flow cytometry after cycle 9. Started Aug 2017; status: active.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2017-000555-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000555-10.